Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 522

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 522
---
 the Amended Note was further amended to increase the aggregate principal amount up to $3.5 million. As of September 30, 2024 and December 31, 2023, the outstanding balance of the Amended Note was $3.1 million and $0.8 million, respectively. For the nine months ended September 30, 2024, the Company recorded interest income of $79,000 related to the Note.

#### Note 8. Commitments and Contingencies
The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.

See Note 7 for discussion on funding commitments on the Note.

#### Note 9. Subsequent Events
The Company has completed an evaluation of all subsequent events through January 8, 2024, the date the unaudited condensed financial statements were issued, to ensure that these unaudited condensed financial statements include appropriate disclosure of events both recognized in the unaudited condensed financial statements and events which occurred but were not recognized in the unaudited condensed financial statements.

On October 23, 2024, the Company entered into a sixth amendment to the Business Combination Agreement to, among other things, reduce the enterprise value associated with the Company to $175 million.

On November 1, 2024, the Company borrowed $0.4 million from Amantes LLC (“Amantes”), a related party of the Company due to having common executives, pursuant to a Loan Agreement between the Company and Amantes (the “Amantes Loan”). The Amantes Loan bears interest at 6% per annum and is due on January 1, 2025. The Company and Amantes have mutually agreed to defer repayment of this loan until the completion of the Company’s business combination with Iris.

On November 27, 2024, the Amended Note was further amended to increase the aggregate principal amount up to $5.0 million.

On November 27, 2024, the Company borrowed an additional $0.3 million from Amantes (the “Additional Amantes Loan”). The Additional Amantes Loan bears interest at 6% per annum and is due on January 1, 2025, which may be extended upon mutual agreement of the parties. The Company and Amantes have mutually agreed to defer repayment of this loan until the completion of the Company’s business combination with Iris